Manufacturer · 2026

Caliway Completes U.S. FDA IND Submission for SUPREME-02 Phase 3 Study of CBL-514

Caliway Biopharmaceuticals (2026). Caliway Completes U.S. FDA IND Submission for SUPREME-02 Phase 3 Study of CBL-514. Company press release.

Company press release

Source: https://www.caliwaybiopharma.com/en/news-detail/Completes-FDA-IND-Submission-SUPREME-02-Pivotal-Phase-3-CBL-514/

Last reviewed . By the PeptIQ team.

Peptides linked in PeptIQ Wiki

This page indexes a published source for discovery and cross-linking. PeptIQ reports what the literature contains and what users track — it does not interpret studies as treatment guidance.